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A B S T R A C T
Purpose
In the general population, increased adiposity is a significant risk factor for colorectal cancer (CRC),
but whether obesity has similar effects in those with hereditary CRC is uncertain. This prospective
study investigated the association between body mass index and cancer risk in patients with
Lynch syndrome (LS).
Patients and Methods
Participants with LS were recruited to the CAPP2 study, in which they were randomly
assigned to receive aspirin 600 mg per day or aspirin placebo, plus resistant starch 30 g per
day or starch placebo (2  2 factorial design). Mean intervention period was 25.0 months, and
mean follow-up was 55.7 months.
Results
During follow-up, 55 of 937 participants developed CRC. For obese participants, CRC riskwas 2.41 (95%
CI, 1.22 to 4.85) greater than for underweight and normal-weight participants (reference group), and CRC
risk increased by 7% for each 1-kg/m2 increase in body mass index. The risk of all LS-related cancers in
obese peoplewas 1.77 (95%CI, 1.06 to 2.96; P .03) greater than for the reference group. In subgroup
analysis, obesitywas associatedwith 3.72 (95%CI, 1.41 to 9.81) greaterCRC risk in patientswith LSwith
MLH1 mutation, but no excess risk was observed in those with MSH2 or MSH6 mutation (P  .5). The
obesity-related excess CRC risk was confined to those randomly assigned to the aspirin placebo group
(adjusted hazard ratio, 2.75; 95% CI, 1.12 to 6.79; P  .03).
Conclusion
Obesity is associated with substantially increased CRC risk in patients with LS, but this risk is
abrogated in those taking aspirin. Such patients are likely to benefit from obesity prevention and/or
regular aspirin.
J Clin Oncol 33. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Lynch syndrome (LS; also known as hereditary
nonpolyposis colon cancer) is an autosomal-
dominant disease and the commonest cause of
hereditary bowel cancer. LS is caused by germline
pathogenic variants in DNA mismatch repair
(MMR) genes MLH1, MSH2, MSH6, and PMS2.
Despite the high penetrance of this condition,
treatment with aspirin (600 mg per day for mean
of 25 months) halved cancer incidence in LS car-
riers after a mean of 55.7 months.1 This finding
suggests that cancer development in LS may be
modulated by exposures, especially those influ-
encing inflammation.
There is substantial evidence that adults with
higher adiposity are at greater risk of several com-
mon cancers, including colorectal cancer (CRC).2,3
A recent systematic review and meta-analysis iden-
tified41prospective studiesofobesity and13 studies
of central obesity (measuredaswaist circumference)
involving approximately 9 million individuals and
92,481patient casesofCRC.Overall, the relative risk
(RR) of CRC for those in the obese versus normal-
weight category was 1.33 (95%CI, 1.25 to 1.42); RR
for those in thehighest versus lowest categoryofWC
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was1.46 (95%CI, 1.33 to1.56).4Therewasnoevidenceofpublication
bias, and the positive association with obesity was evident for both
sexes, several geographic regions, andcancersof colonandrectum.4 In
patients with LS, a prospective cohort study from the Netherlands
found that compared with normal weight, there was a statistically
significant association between overweight (body mass index [BMI]
 25 kg/m2) and colorectal adenoma (benign precursor of CRC) risk
in men but not in women.5 These findings are in line with an earlier
Canadian case-control study,which reported thatmenwith andwith-
out clinically defined familial risk of cancer (LS diagnosed using Am-
sterdam6orBethesda7 criteria)were at significantly greaterCRCrisk if
overweight (BMI 25 kg/m2) or obese (BMI 30 kg/m2) compared
with normalweight.8 As in theDutch study, therewas no relationship
between adiposity and LS-related bowel cancer in women.8 In addi-
tion, a retrospective analysis of data from participants in the National
Cancer Institute Colon Cancer Family Registry with germline MMR
mutation showed that increased BMI at age 20 years was associated
with subsequent higher CRC risk.9
Table 1. Baseline Characteristics of Participants With LS
Characteristic
Colorectal
Adenoma
Data Set
(n  746)
No. (%)
Colorectal
Cancer
Data Set
(n  937)
No. (%)
Male sex 336 (45.0) 412 (44.0)
Age at cohort entry, years
Mean 45.2 45.2
SD 10.8 11.0
Median 44.9 44.9
Q1-Q3 36.7-53.2 36.3-53.3
Age quartile, years
21.5-36.25 179 (24.0) 234 (25.0)
36.26-44.85 192 (25.7) 234 (25.0)
44.86-53.32 191 (25.6) 234 (25.0)
 55.33 184 (24.7) 235 (25.0)
Follow-up time, months
Mean 28.0 55.7
SD 11.2 31.2
Median 25.0 53.1
Q1-Q3 23.4-30.3 29.4-78.3
Time receiving intervention, months
Mean 29.0 25.0
SD 11.5 13.4
Median 25.3 24.4
Q1-Q3 23.7-33.5 15.9-28.9
BMI, kg/m2
Mean 25.8 25.9
SD 4.7 4.8
Median 25.1 25.2
Interquartile range 22.5-28.2 22.7-28.4
BMI category, kg/m2
Underweight ( 18.5) 12 (1.6) 14 (1.5)
Normal weight (18.5-24.9) 341 (47.7) 418 (44.6)
Overweight (25.0-29.9) 254 (34.1) 321 (34.3)
Obese ( 30) 112 (15.1) 143 (15.3)
Missing 27 (3.6) 41 (4.4)
MMR gene mutation
Clinical diagnosis 132 (17.7) 163 (17.4)
MLH1 358 (48.0) 464 (49.5)
MSH2 235 (31.5) 284 (30.3)
MSH6 21 (2.82) 26 (2.8)
Clinical center (geographic region)
Northern Europe 334 (44.8) 423 (45.1)
United Kingdom 218 (29.2) 277 (29.6)
Other 194 (26.0) 237 (25.3)
Intervention
Aspirin
Placebo 343 (46.0) 434 (46.3)
Aspirin 350 (46.9) 427 (45.6)
Not randomly assigned 53 (7.1) 76 (8.1)
Resistant starch
Placebo 369 (49.5) 455 (48.6)
Resistant starch 358 (48.0) 463 (49.4)
Not randomly assigned 19 (2.5) 19 (2.0)
Abbreviations: BMI, body mass index; LS, Lynch syndrome; MMR, mismatch
repair; Q, quartile; SD, standard deviation.
Table 2. HRs for Developing Colorectal Adenoma by BMI Category
Stratified by Sex in Participants With LS
Variable
Unadjusted HR
HR (95% CI)
Adjusted HR
HR (95% CI)
Participants with adenoma of total
participants 117 of 719 117 of 719
BMI, kg/m2 (continuous variable
HR per unit BMI) 1.03 (0.99 to 1.06) 1.02 (0.98 to 1.06)
Under- and normal weight
( 25) 1.00 1.00
Overweight (25-29.99) 1.05 (0.70 to 1.58) 0.98 (0.65 to 1.48)
Obese ( 30) 1.39 (0.85 to 2.29) 1.28 (0.77 to 2.12)
Women 56 of 389 56 of 389
BMI, kg/m2 (continuous
variable) 1.04 (0.99 to 1.08) 1.03 (0.99 to 1.07)
Under- and normal weight
( 25) 1.00 1.00
Overweight (25-29.99) 1.18 (0.65 to 2.16) 1.23 (0.66 to 2.28)
Obese ( 30) 1.46 (0.73 to 2.93) 1.38 (0.67 to 2.83)
Men 61 of 330 61 of 330
BMI, kg/m2 (continuous
variable) 0.99 (0.93 to 1.07) 0.99 (0.93 to 1.07)
Under- and normal weight
( 25) 1.00 1.00
Overweight (25-29.99) 0.89 (0.51 to 1.55) 0.82 (0.47 to 1.46)
Obese ( 30) 1.24 (0.61 to 2.51) 1.17 (0.56 to 2.43)
MLH1 mutation 55 of 339 55 of 339
Under- and normal weight
( 25) 1.00 1.00
Overweight (25-29.99) 0.70 (0.38 to 1.29) 0.67 (0.36 to 1.25)
Obese ( 30) 1.25 (0.59 to 2.65) 1.21 (0.55 to 1.11)
MSH2 mutation 30 of 232 30 of 232
BMI, kg/m2 (continuous
variable) 1.04 (0.96 to 1.12) 1.02 (0.94 to 1.11)
Under- and normal weight
( 25) 1.00 1.00
Overweight (25-29.99) 0.76 (0.31 to 1.86) 0.64 (0.25 to 1.62)
Obese ( 30) 1.64 (0.70 to 3.88) 1.29 (0.53 to 3.15)
Clinical diagnosis 30 of 127 30 of 127
BMI, kg/m2 (continuous
variable) 1.04 (0.99 to 1.10) 1.04 (0.99 to 1.10)
Under- and normal weight
( 25) 1.00 1.00
Overweight (25-29.99) 2.32 (1.03 to 5.20)† 2.53 (1.10 to 5.83)†
Obese ( 30) 1.17 (0.40 to 3.45) 1.32 (0.42 to 4.13)
Abbreviations: BMI, body mass index; HR, hazard ratio; LS, Lynch syndrome.
Adjusted for age, starch, aspirin, geographic region, mismatch repair gene,
and sex, where appropriate.
†Significant at P  .02.
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Several plausible mechanisms link higher adiposity with greater
CRC risk, including those that cause genomic damage (eg, inflamma-
tion and oxidative stress), those that promote cell proliferation (eg,
raised concentrations of insulin-like growth factors), and those that
affect immunosurveillance.10,11 In addition, the gutmicrobiomemay
mediate both increased adiposity and greater CRC risk.12,13 Our hy-
pothesis is that because of their reduced ability to combat DNA dam-
age, overweight or obese patients with LS may be at enhanced cancer
risk comparedwith normal-weight patients with LS.We aimed to test
that hypothesis in a prospective study of patients with LS who were
enrolled onto the CAPP2 (Colorectal Adenoma/Carcinoma Preven-
tion Programme 2) study, a randomized controlled trial of effects of
intervention with aspirin and/or resistant starch (RS) using a 2  2
factorial design.1,14,15
PATIENTS AND METHODS
Between January 1999 andMarch 2005, 937 LS carriers started intervention in
the CAPP2 study.14,16 Eligible patients were proven carriers of DNA MMR
mutation ormembers of a family thatmet the Amsterdamdiagnostic criteria6
andhad a personal history of a cured LSneoplasmbut an intact colon. Eligible
participants (in 43 centers across 16 countries) were randomly assigned sepa-
rately in a factorial design to aspirin 600 mg per day and/or RS 30 g per day,
with placebo controls. The primary end point was the incidence of bowel
neoplasia. The number, size, and histologic status of all colonic adenomas and
carcinomas were recorded and compared between treatment and placebo
groups.14The interventionperiod lastedameanof25.0months (median,24.4;
quartile [Q] 1 to Q3, 15.9 to 28.9 months), and the study had a preplanned
design for 10-year follow-up. At the time of our analysis, the earliest enrolled
participants had reached the 10-year threshold, andmean follow-up was 55.7
months (median, 53.1; Q1 to Q3, 29.4 to 78.3 months).1
Cancer incidence analysis focused on follow-up of the 937 patients in
whom cancer outcome data were recorded from their date of entry into the
CAPP2 studyuntil the last knowndate forwhich the local center had informa-
tion with respect to cancer diagnosis. Adenoma incidence was recorded in
detail for 746 participants who completed the intervention phase of the study.
Outside this group, andbeyond the intervention, adenoma incidencewasonly
partially recorded andwas excluded fromour analysis. At recruitment, partic-
ipants were asked height and weight. Participant adiposity was determined
using the WHO criteria for BMI categories (ie, underweight, 18.5; normal
weight, 18.5 to 24.99; overweight, 25 to 29.99; and obese, 30 kg/m2).17 For
analysis purposes in this study, BMI was treated as a quantitative trait, al-
though for clarity, categorical results are also provided, in which the under-
weight (n14) andnormal-weight groups (n418)were combined (BMI
24.99 kg/m2) as the reference group.
Statistical Analysis
Theanalysiswasbasedon time tofirst eventusing life-tablemethods and
Coxproportional hazards. The life-table analysis used the endof follow-up for
each participant as the time of first event, if affected; for those unaffected, the
last recorded contact date at which the clinical status of the participant was
known was used. The analysis considered the following events: adenoma
occurrence (this analysis considereddata from intervention timeperiodonly);
CRC incidence during both intervention and follow-upphases (thosewithout
diagnosis of CRCwere considered unaffected at this last clinical contact); and
LS cancer (same as for CRC incidence but including all cancers within syn-
drome). The analysis strategy was designed to test the hypothesis that BMI
increases the risk of neoplasia in those with LS. Cox proportional hazards
modelswereused to estimate crudeandadjustedhazard ratios (HRs) and95%
CIs for the association between BMI and risk of LS-related neoplasia (ade-
noma and cancer), adjusting for age, sex, geographic region, MMR gene
mutation, and intervention (aspirin orRS). The analyseswere repeated for sex
and MMR gene mutation subgroups separately. All analyses used STATA
software (version 10; STATA, College Station, TX).
RESULTS
Table 1 summarizes the baseline characteristics for participants with
LS in the CAPP2 study. The median age at study entry was 44.9 years
(Q1 to Q3, 36 to 53 years) in both adenoma and CRC data sets.
Women made up 55% and 56% of participants in the adenoma and
Table 3. HRs for Developing Cancer by BMI Category Stratified by Sex in Participants With LS
Variable
CRC Incidence
Adjusted HR (95% CI)
Incidence of Other LS-Related
Cancers (excluding CRC)
Adjusted HR (95% CI)
Incidence of All
LS-Related Cancers
Adjusted HR (95% CI)
Participants with cancer diagnosis of total participants with follow-up 54 of 896 43 of 896 95 of 896
BMI, kg/m2 (quantitative variable) 1.07 (1.02 to 1.13)† 1.02 (0.96 to 1.08) 1.05 (1.01 to 1.09)‡
Under- and normal weight ( 25) 1.00 1.00 1.00
Overweight (25-29.99) 1.09 (0.57 to 2.11) 0.59 (0.26 to 1.31) 0.87 (0.53 to 1.44)
Obese ( 30) 2.34 (1.17 to 4.67)‡ 1.23 (0.58 to 2.63) 1.81 (1.08 to 3.03)§
Women 25 of 494 36 of 494 60 of 494
BMI, kg/m2 (quantitative variable) 1.06 (0.99 to 1.13) 1.03 (0.97 to 1.09) 1.04 (0.99 to 1.09)
Under- and normal weight ( 25) 1.00 1.00 1.00
Overweight (25-29.99) 0.66 (0.20 to 2.13) 0.80 (0.33 to 1.93) 0.74 (0.37 to 1.50)
Obese ( 30) 2.36 (0.91 to 6.20) 1.58 (0.68 to 3.66) 1.77 (0.93 to 3.37)
Men 29 of 402 7 of 402 35 of 402
BMI, kg/m2 (quantitative variable) 1.12 (1.02 to 1.24)‡ 0.84 (0.65 to 1.08) 1.08 (0.98 to 1.18)
Under- and normal weight ( 25) 1.00 1.00 1.00
Overweight (25-29.99) 1.45 (0.61 to 3.43) 0.16 (0.02 to 1.39) 1.01 (0.47 to 2.18)
Obese ( 30) 2.41 (0.85 to 6.81) 0.31 (0.03 to 3.32) 1.71 (0.67 to 4.37)
Abbreviations: BMI, body mass index; CRC, colorectal cancer; HR, hazard ratio; LS, Lynch syndrome.
Adjusted for age, starch, aspirin, geographic region, mismatch repair gene, and sex, where appropriate.
†Significant at P  .007.
‡Significant at P  .02.
§Significant at P  .03.
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cancer data sets, respectively. In both data sets, approximately 80% of
participants hadmutation in MLH1 or MSH2, 34%were overweight,
and 15%were obese (BMI 30 kg/m2; Table 1).
Obesity and Risk of Colorectal Adenoma
Of 719 people (of 746 who completed exit colonoscopy from
intervention study) forwhomBMIdatawere available, 117developed
colorectal adenoma during the intervention phase (median, 25.3
months;Table2).Overall, therewasanonsignificant increased risk for
colorectal adenomaamongobeseparticipants (HR,1.28; 95%CI, 0.77
to 2.12) comparedwith the reference group (HR adjusted for age, sex,
aspirin andRS intake, geographic region, andMMRgene status;Table
2). A nonsignificant increased risk in obese participants was found for
bothmen(HR,1.17;95%CI,0.56 to2.43)andwomen(HR,1.38;95%
CI, 0.67 to 2.83) and for both MLH1 (HR, 1.21; 95%CI, 0.55 to 2.63)
and MSH2 (HR, 1.29; 95%CI, 0.53 to 3.15) genemutation carriers.
Obesity and Risk of CRC
During longer-term follow-up (median, 53.1months), 55 of the
937 participants in the CAPP2 study developed CRC (Table 3; BMI
data were not available for one patient with CRC). Risk of CRC
development was 9% higher in the overweight compared with refer-
ence group, but the effect was not statistically significant (HR, 1.09;
95% CI, 0.57 to 2.11; P .8). However, for obese participants, CRC
risk was 2.34 (95% CI, 1.17 to 4.67; P  .02), and significantly,
greater than for the reference group (HR adjusted for age, sex, aspirin
and RS intake, geographic region, andMMR gene status; Table 3; Fig
1A). When the analysis was conducted for each sex separately, CRC
risk was 2.41 (95% CI, 0.85 to 6.81) and 2.36 (95% CI, 0.91 to
6.20) greater for obese men and women, respectively, than for the
corresponding reference group. With BMI as a continuous variable,
CRC risk increased significantly with each unit of BMI in men (HR,
1.12; 95% CI, 1.02 to 1.24; P  .02) but was marginally weaker in
women (HR, 1.06; 95% CI, 0.99 to 1.13; P  .09). There was no
statistically significant interaction between sex and BMI category in
CRC risk (LR 2 with 2 df, 1.37; P .24; data not shown).
TheadjustedHRs for theassociationsbetweenBMIandCRCrisk
stratified byMMR genemutation are listed in Table 4. Obese partici-
pants with MLH1 gene mutation had significantly higher CRC risk
compared with the reference group (HR, 3.72; 95% CI, 1.41 to 9.81;
P .008). In contrast, CRC risk was not raised significantly in obese
participants with MSH2 mutation (HR, 1.59; 95%CI, 0.47 to 5.44).
Obesity and Risk of LS-Related Cancers
The secondary analysis considered all LS-related cancers and
non-CRC LS cancers, including endometrial, ovarian, and pancreatic
cancers and cancers of the brain, small bowel, gallbladder, ureter,
stomach, and kidney.18 After adjustment, there were no significant
associations between BMI category and risk of non-CRC LS cancers
formen, women, or all participants (Table 3). In addition, there were
no significant adjusted associations between BMI category and risk of
other LS cancers when stratified by MMR gene mutation (Table 4).
Details of individual LS cancer incidence in this study have been
reported by Burn et al.1
WhenCRCwas included with all other LS cancers, obesity was a
significant risk factor for all LS-related cancer incidence (HR, 2.18;
95%CI, 1.33 to 3.58; P .002). This effect remained significant (HR,
1.81; 95%CI, 1.08 to 3.03; P .03) after adjusting for other variables
(age, sex, aspirin and RS intake, geographic region, and MMR gene;
Table 3; Fig 1B). In addition, among MLH1 gene mutation carriers,
obesity increased the risk of all LS-related cancers (HR, 2.77; 95%CI,
1.39 to 5.52; P  .004), but this association became nonsignificant
after adjustment for all covariates (HR, 1.76; 95% CI, 0.85 to 3.65;
Table 4).
Effects of Aspirin
Given the evidence that aspirin treatment reduces cancer risk in
patients with LS, we carried out separate analyses of effects of BMI
among those randomly assigned to aspirin and those to aspirin pla-
cebo in the CAPP2 study (Table 5). In patients with LS randomly
assigned to placebo, there was a significant association between in-
creased BMI andCRC risk (HR, 1.10; 95%CI, 1.03 to 1.17;P .001),
whereas there was no evidence of an increased risk among those
randomly assigned to aspirin (HR, 1.00; 95%CI, 0.90 to 1.12; nonsig-
nificant). Indeed, these two effect sizes are significantly different (P
0
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Fig 1. Time to first (A) colorectal cancer (CRC) and (B) Lynch syndrome cancer
in participants stratified by body mass index category.
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.01), suggesting that aspirin changes the relationship between BMI
and CRC risk, with no evidence of any association for those receiving
aspirin.
DISCUSSION
In this prospective study, we observed a statistically significant
positive association between BMI at baseline and subsequent CRC
risk in participantswith LS. Thosewhowere obese had 2.34 (95%
CI, 1.17 to 4.67) greater risk of CRC (P .02) than those of normal
weight, and there was a linear increase inHR for CRCwith increas-
ing BMI. The greater CRC risk associated with each 1-kg/m2 in-
crease in BMI seemed to be stronger for men (HR, 1.12; 95% CI,
1.02 to 1.24; P .02) than for women (HR, 1.06; 95% CI, 0.99 to
1.13; Table 3), although this difference was not statistically signif-
icant. This seemingly sex-specific relationship between adiposity
and colorectal neoplasia among patients with LS is consistent with
previous observations (Appendix Table A1, online only). In a
case-control study, Campbell et al8 reported significantly greater
CRC risk in obese men, but not women, with a clinical diagnosis
of LS. Similarly, in a short-term prospective study (median
follow-up, 20 months) of those with no previous colorectal
neoplasia, Botma et al5 observed that the risk of colorectal
adenomatous polyps was increased significantly in overweight
and obese men, but not women, who carried germline muta-
tions in MMR genes. In the CAPP2 study, the increased cancer
risk with increased BMI in men but not women was restricted to
the colorectum (Table 3).
There is substantial evidence that greater adiposity is associated
with higher CRC risk in the general population. A recent meta-
analysis of 41 prospective studies involving approximately 9 million
participants and 85,935 patient cases ofCRC revealed anoverall RRof
1.33 (95% CI, 1.25 to 1.42) in those in the obese versus normal BMI
category.4When stratified by sex, CRC risk among obese participants
was greater in men (RR, 1.47; 95% CI, 1.36 to 1.58) than in women
(RR, 1.15; 95% CI, 1.08 to 1.23).4 This observation of sex-dependent
Table 4. HRs for Developing Cancer by BMI Category Stratified by MMR Gene in Participants With LS
Variable
CRC Incidence
Adjusted HR (95% CI)
Incidence of Other LS-Related
Cancers (excluding CRC)
Adjusted HR (95% CI)
Incidence of All
LS-Related Cancers
Adjusted HR (95% CI)
MLH1 mutation 28 of 438 22 of 438 50 of 438
BMI, kg/m2 (quantitative variable) 1.12 (1.04 to 1.21)† 0.95 (0.86 to 1.05) 1.05 (0.99 to 1.12)
Under- and normal weight ( 25) 1.00 1.00 1.00
Overweight (25-29.99) 1.19 (0.47 to 3.01) 0.39 (0.13 to 1.14) 0.75 (0.37 to 1.48)
Obese ( 30) 3.72 (1.41 to 9.81)‡ 0.64 (0.19 to 2.19) 1.76 (0.85 to 3.65)
MSH2 mutation 20 of 276 16 of 276 35 of 276
BMI, kg/m2 (quantitative variable) 1.01 (0.91 to 1.12) 1.09 (1.00 to 1.20)§ 1.04 (0.97 to 1.11)
Under- and normal weight ( 25) 1.00 1.00 1.00
Overweight (25-29.99) 1.26 (0.44 to 3.60) 1.21 (0.30 to 4.92) 1.33 (0.58 to 3.06)
Obese ( 30) 1.59 (0.47 to 5.44) 4.34 (1.15 to 16.4) 2.02 (0.84 to 4.85)
Abbreviations: BMI, body mass index; CRC, colorectal cancer; HR, hazard ratio; LS, Lynch syndrome; MMR, mismatch repair.
Adjusted for age, sex, starch, aspirin, and geographic region.
†Significant at P  .002.
‡Significant at P  .008.
§Significant at P  .05.
Table 5. HRs for Developing Cancer by BMI Category Stratified by Aspirin Treatment in Participants With LS
Variable
CRC Incidence
Adjusted HR (95% CI)
Incidence of Other LS-Related
Cancers (excluding CRC)
Adjusted HR (95% CI)
Incidence of All
LS-Related Cancers
Adjusted HR (95% CI)
Placebo 36 of 485 28 of 485 62 of 485
BMI, kg/m2 (quantitative variable) 1.10 (1.03 to 1.17)† 1.03 (0.96 to 1.10) 1.06 (1.02 to 1.11)‡
Under- and normal weight ( 25) 1.00 1.00 1.00
Overweight (25-29.99) 1.46 (0.63 to 3.78) 0.46 (0.16 to 1.29) 0.91 (0.49 to 1.70)
Obese ( 30) 2.75 (1.12 to 6.75)§ 1.33 (0.51 to 3.52) 1.91 (1.00 to 3.69)
Aspirin 18 of 411 15 of 411 33 of 411
BMI, kg/m2 (quantitative variable) 1.00 (0.90 to 1.12) 0.99 (0.89 to 1.10) 1.00 (0.93 to 1.08)
Under- and normal weight ( 25) 1.00 1.00 1.00
Overweight (25-29.99) 0.74 (0.22 to 3.46) 0.89 (0.21 to 3.77) 0.87 (0.36 to 2.10)
Obese ( 30) 2.00 (0.61 to 6.70) 1.14 (0.30 to 4.27) 1.58 (0.66 to 3.81)
Abbreviations: BMI, body mass index; CRC, colorectal cancer; HR, hazard ratio; LS, Lynch syndrome.
Adjusted for age, sex, starch, mismatch repair gene status, and geographic region.
†Significant at P  .001.
‡Significant at P  .006.
§Significant at P  .03.
Significant at P  .05.
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greater CRC risk among obesemen in the general population accords
with our current findings in patients with LS and with reports from
other observational studies (Appendix Table A1, online only). In
addition, in the general population, there is a positive dose-response
relationship between BMI andCRC risk; for each 2-kg/m2 increase in
BMI, CRC risk increased by 7% (95%CI, 4% to 10%).19 Importantly,
among those with LS in our study, each 1-kg/m2 increase in BMI was
associatedwith7%increasedCRCrisk(ie, greateradiposity inpatients
with LS was associated with twice the excess risk for CRC of that seen
in general population).
The mechanism responsible for the greater cancer risk among
obese patientswith LS is not known.However, given the germline loss
of DNA MMR capacity in LS, it may be hypothesized that adverse
sequelae of greater body fatness (eg, chronic low-level inflammation)
have a promoting effect on those stem cells that have accumulated
DNA damage because of this dysfunctional repair system.
Up to 20% of unselected CRC tumors showmicrosatellite insta-
bility (MSI)—the cardinal feature of loss of MMR function—but in
the vastmajority of such tumors, theMMRdysfunction is the result of
epigenetic silencing of the MLH1 gene by promotermethylation.20 In
a population-based case-control study, Slattery et al21 found that in-
creased BMI was associated with greater risk of microsatellite-stable
tumors but not of tumors exhibiting MSI. This observation is sup-
ported by findings from patients with stage II or III colon carcinoma
participating inNorthCentralCancerTreatmentGroupandNational
Surgical Adjuvant Breast and Bowel Project adjuvant chemotherapy
trials, where obesity was associated with a significantly lower rate of
tumors showing deficient MMR.22 A more recent population-based
case-control study reported that the risk of both microsatellite-stable
and MSI-low, but not MSI-high, tumors increased significantly with
increasing BMI.23 In both of these studies, it is probable that MMR
dysfunction in all, or most, CRC tumors was the result of somatic
epigenetic-based loss of MMR; the tumorigenesis stage at which the
loss occurred is unknown. In contrast, in LS, germline loss of MMR
capacity drives tumorigenesis fromthe earliest stages, and it is possible
that this earlyMMRdysfunction increases susceptibility to the tumor-
promoting effects of greater adiposity. Interestingly, we found that
CRC risk was increased significantly in obese patients with LS with
germline mutation in MLH1 (HR, 3.72; 95% CI, 1.41 to 9.81; P 
.008) but not in those with MSH2 mutation (Table 4). In the short-
term prospective study by Botma et al,5 there was a trend (not signif-
icant) toward a greater excess of adenomatous polyps in overweight
and obese patients with LS with germline mutation in MLH1 but not
inMSH2 comparedwith thosewith BMI 25 kg/m2. A retrospective
analysis of data from participants in the National Cancer Institute
ColonCancer Family Registry also found a significantly increasedHR
with increased BMI for MLH1 mutation carriers (HR, 1.36; 95% CI,
1.04 to 1.77) but not for those with mutation in MSH2, MSH6, or
PMS2.9 After recognition of DNA damage by a pair of MutS homo-
logues, the MLH1 protein forms a heterodimer with PMS2, which
leads to the initiation of MMR.24 Because all MMR proteins are nec-
essary for successful DNA repair, the mechanistic basis for the seem-
ingly greater susceptibility of MLH1 mutation carriers to the adverse
effects of obesity is not known.
Interestingly, our intervention study showed some evidence that
the excess CRC risk in patients with LS is abrogated by regular aspirin
consumption. Data from the Aspirin/Folate Polyp Prevention Study
suggested that aspirin 325 mg per day might be more effective in
preventingadvancedcolorectal adenomas in thosewhoareobese (RR,
0.44; 95%CI, 0.17 to 1.10) comparedwith normal-weight individuals
(RR, 1.23; 95%CI, 0.55 to 2.77), but the wide CIs precluded a defini-
tive conclusion.25 In addition, a case-control study of women in the
Australian National Endometrial Cancer Study reported that aspirin
might reduce the risk of endometrial cancer among obese women.26
A limitation of our study is that height and weight (used for BMI
estimation)wereself-reported.It iswell recognizedthatheightandweight
tendtobeover-andunderestimated,respectively, soabsoluteestimatesof
obesity can be underestimated.27 However, the sensitivity and specificity
of self-reportedheight andweight in detecting obesity are good: 0.83 and
1.00, respectively.27This suggests thatanyerrors inBMIestimation inour
study were likely to result in conservative estimates of the association
betweenobesity and increased cancer risk in patientswith LS.
In summary, obesity is associated with greater risk of CRC in
patients with LS. The excess risk of CRCwith increasing adipositywas
twice as great inpatientswithLS ashas beenobservedbyothers for the
general population. However, this increased CRC risk was significant
inmenonly, andwe observed that aspirin abrogated the excess cancer
risk associatedwith obesity in patients with LS. These findings suggest
that, in addition to recommendedbowel surveillance, patientswithLS
are likely to benefit substantially from prevention—or effective
treatment—of obesity and from regular aspirin use.
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GLOSSARY TERMS
Lynch syndrome: hereditary nonpolyposis colorectal cancer
(HNPCC). A cancer syndrome characterized by Henry T. Lynch
in 1966, this genetic condition has a high risk of colon cancer as
well as other cancers including endometrial, ovary, stomach,
small intestine, hepatobiliary tract, upper urinary tract, brain,
and skin.
Mismatch repair: one of four major pathways of DNA repair in
mammalian cells. Mismatch repair recognizes and corrects errors in
DNA replication leading to single base-pair mismatches or insertions/
deletions in small repetitive tracts of DNA known as microsatellites.
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Appendix
Table A1.Outcomes From Previous Studies of Associations Between BMI and Colorectal Neoplasia in Patients With LS
Reference Study Design Outcome Sex BMI (kg/m2)
Risk Estimate (95% CI)
OR HR
Diergaarde et al† Case control CRC Both  23.2 1 (referent)
 25.5 0.90 (0.4 to 1.8)
Campbell et al8‡ Case control CRC M 18.5-24.99 1 (referent)
25-29.99 1.25 (0.97 to 1.61)
 30 1.83 (1.33 to 2.51)
F 18.5-24.99 1 (referent)
25-29.99 1.03 (0.80 to 1.33)
 30 0.85 (0.62 to 1.16)
Win et al9§ Retrospective CRC Both  18.5 1.04 (0.00 to 1.64)
18.5-24.99 1 (referent)
25.0-29.99 1.12 (0.78 to 1.62)
 30 2.35 (1.30 to 4.23)
Botma et al5§ Prospective (incident cohort) Adenomatous polyps M  25 1 (referent)
 25 5.19 (1.30 to 20.80)
F  25 1 (referent)
 25 0.78 (0.20 to 3.05)
Prospective (prevalent cohort) Adenomatous polyps M  25 1 (referent)
 25 1.00 (0.42 to 2.38)
F  25 1 (referent)
 25 0.91 (0.29 to 2.91)
Abbreviations: BMI, body mass index; CRC, colorectal cancer; HR, hazard ratio; LS, Lynch syndrome; OR, odds ratio.
Diergaarde B et al: Clin Gastroenterol Hepatol 5:736-742, 2007.
†Both mismatch repair gene mutation carriers (n  73) and untested individuals suspected of having LS (n  175).
‡Clinically defined familial risk of cancer (according to Amsterdam or revised Bethesda criteria for LS).
§Known carriers of germline mutations in mismatch repair genes.
Estimated from self-reported height and weight at approximately age 20 years.
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